

Page 6, line 1 change "increse" to read --increase--

Page 6, line 16 after "example" insert --,--

Page 7, line 16, Section B change "(Anhydriys)" to read --
(Anhydrous)

Page 8, line 16 change "This" to read --The--

Page 8, line 17 after "examples" insert --was--

Page 10, line 8 after "was prepared" insert the following:

---Benzyl Alcohol NF 1.50ml
Sodium Chloride USP 0.82g
Methyl Cellulose (4000 cps.) 1.33g
Acetic Acid NF 0.10g
Sodium Acetate (Anhydrous) 0.27g
Sorbitol Solution USP 5.00ml
Cyanocoabalamin USP 0.10g
Water, Purified USP q.s. 100.000ml

a
This composition was tested in three humans as described in
the previous example. The nasal administration of 200ug of B₁₂
in 0.2cc gave the following serum B₁₂ levels:--

Page 11, line 13 change "Bengulkonium" to read --
Benzalkonium--

Page 11, line 16 change "intrumural" to read --intranasal--

Page 11, line 25 change "Baseline" to read --baseline--

REMARKS

A number of typographical errors have been corrected.
Additionally, a section which appeared in the parent application
and was inadvertently omitted at the time of preparing the above
identified continuation in part application has been resubmitted.
In that connection the examiner is respectfully requested to
compare lines 1 through 11 on page 11 of the parent application
with the amendment proposed for page 10 line 8 of this
application after "prepared".

I hereby certify that this correspondence is being deposited with
the United States Postal Service
as first class mail in an envelope
addressed to Commissioner of Patents
and Trademarks, Washington, D. C.
20231, on 1-12-81.

Date: 1-12-81

Henry T. Burke
Henry T. Burke, Reg. No. 18975

Respectfully submitted,

Henry T. Burke
Henry T. Burke, Reg. No. 18975
c/o Wyatt, Gerber et al
261 Madison Avenue
New York, NY 10016
Tel: (212) 687-0911